WO2005058233B1 - Methods for treatment of acute pancreatitis - Google Patents
Methods for treatment of acute pancreatitisInfo
- Publication number
- WO2005058233B1 WO2005058233B1 PCT/US2004/041368 US2004041368W WO2005058233B1 WO 2005058233 B1 WO2005058233 B1 WO 2005058233B1 US 2004041368 W US2004041368 W US 2004041368W WO 2005058233 B1 WO2005058233 B1 WO 2005058233B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- secretin
- pharmaceutical composition
- patient
- acute pancreatitis
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Abstract
The invention relates generally to methods for treating acute pancreatitis in patients. The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising secretin and a pharmaceutically acceptable carrier.
Claims
AMENDED CLAIMS
[received by the International Bureau on 23 December 2005 (23.12.05); original claim 1 amended; original claim 10 cancelled remaining claims unchanged (4 pages)]
+ STATEMENT
WHAT IS CLAIMED IS:
1. A method for treating acute pancreatitis in a human patient, comprising the step of administering to a human patient suffering from acute pancreatitis a therapeutically effective amount of a pharmaceutical composition comprising secretin and a pharmaceutically acceptable qarrier, said pharmaceutical composition capable of treating said acute pancreatitis in said human
patient.
t. The method of claim 1 , wherein said secretin is a naturally occurring form of secretin.
3. The method of claim 1 , wherein said secretin is a synthetic form of secretin.
4, The method of claim 3, wherein said synthetic form of secretin is synthetic porcine secretin.
$. The method of claim 1 , wherein said secretin is a genetically recombined form of porcine, bovine, or human secretin.
6. The method of claim 1 , wherein the amount of secretin administered to said patient in said pharmaceutical composition ranges from 2 to 480 micrograms per day.
7. The method of claim 6, wherein the amount of secretin administered to said patient in said pharmaceutical composition ranges from 24 to 160 micrograms per day.
19
8. The method of claim 7, wherein the amount of secretin administered to said patient in said pharmaceutical composition ranges from 48 to 128 micrograms per day.
$ . The method of claim 1, wherein said pharmaceutically acceptable carrier is selected from fie group consisting of ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride (saline), zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene- polyoxypropylene-block polymers, polyethylene glycol and wool fat, and combinations thereof.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52943303P | 2003-12-12 | 2003-12-12 | |
| US60/529,433 | 2003-12-12 | ||
| US11/007,490 US7381698B2 (en) | 2003-12-12 | 2004-12-08 | Methods for treatment of acute pancreatitis |
| US11/007,490 | 2004-12-08 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2005058233A2 WO2005058233A2 (en) | 2005-06-30 |
| WO2005058233A3 WO2005058233A3 (en) | 2005-12-29 |
| WO2005058233B1 true WO2005058233B1 (en) | 2006-03-02 |
Family
ID=34656445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2004/041368 Ceased WO2005058233A2 (en) | 2003-12-12 | 2004-12-10 | Methods for treatment of acute pancreatitis |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US7381698B2 (en) |
| WO (1) | WO2005058233A2 (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6632429B1 (en) * | 1999-12-17 | 2003-10-14 | Joan M. Fallon | Methods for treating pervasive development disorders |
| US20070053895A1 (en) | 2000-08-14 | 2007-03-08 | Fallon Joan M | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
| US8030002B2 (en) | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
| US8100844B2 (en) * | 2002-04-25 | 2012-01-24 | Ultraflex Systems, Inc. | Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint |
| US20060198838A1 (en) * | 2004-09-28 | 2006-09-07 | Fallon Joan M | Combination enzyme for cystic fibrosis |
| US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
| US20070116695A1 (en) * | 2005-09-21 | 2007-05-24 | Fallon Joan M | Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders |
| US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
| US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
| US20090324730A1 (en) * | 2008-06-26 | 2009-12-31 | Fallon Joan M | Methods and compositions for the treatment of symptoms of complex regional pain syndrome |
| US9320780B2 (en) * | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
| US11016104B2 (en) * | 2008-07-01 | 2021-05-25 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
| US10776453B2 (en) * | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
| US20100092447A1 (en) * | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
| EP3064217B1 (en) | 2009-01-06 | 2018-04-18 | Galenagen, LLC | Compositions comprising protease, amylase and lipase for use in the treatment of staphylococcus aureus infections |
| GB2480773B (en) | 2009-01-06 | 2013-12-11 | Curelon Llc | Compositions for the treatment of diarrhea caused by virulent E. coli infections |
| US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| WO2011050135A1 (en) | 2009-10-21 | 2011-04-28 | Curemark Llc | Methods and compositions for the prevention and treatment of influenza |
| EP3305317B1 (en) | 2011-04-21 | 2020-06-24 | Curemark, LLC | Compounds for the treatment of neuropsychiatric disorders |
| US9962430B2 (en) | 2012-02-15 | 2018-05-08 | Chirhoclin, Inc. | Methods for treating pain associated with chronic pancreatitis |
| US11406718B2 (en) | 2012-05-29 | 2022-08-09 | Chirhoclin, Inc. | Methods of detecting pancreobiliary ductal leaks |
| US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
| WO2018191233A1 (en) | 2017-04-10 | 2018-10-18 | Curemark, Llc | Compositions for treating addiction |
| RU2738669C1 (en) * | 2020-07-27 | 2020-12-15 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Ижевская государственная медицинская академия" Министерства здравоохранения Российской Федерации | Method of treating acute pancreatitis |
| US11744878B2 (en) | 2020-08-19 | 2023-09-05 | Chirhoclin, Inc. | Methods for treatment of COVID-19 syndrome |
| US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
| CN113424795B (en) * | 2021-05-24 | 2022-09-09 | 四川大学华西医院 | Construction method and use of an acute pancreatitis animal model |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4443434A (en) | 1982-08-18 | 1984-04-17 | American Home Products Corporation | Antiulcer agent |
| JPS59186916A (en) | 1983-04-06 | 1984-10-23 | Aiji Noda | Remedy for pancreatolithiasis |
| US5094837A (en) * | 1990-01-22 | 1992-03-10 | Wayne State University | Method for use of magnetic resonance imaging to image pancreas using secretin |
| US6197746B1 (en) | 1998-05-19 | 2001-03-06 | Repligen Corporation | Method of using secretin for treating autism |
| JP2002501616A (en) * | 1997-05-19 | 2002-01-15 | リプリゲン コーポレーション | Methods to assist in differential diagnosis and treatment of autistic syndrome |
| US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
| US6534063B1 (en) | 1999-12-17 | 2003-03-18 | Joan M. Fallon | Methods for treating pervasive development disorders |
| US6143306A (en) | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
| US6261572B1 (en) | 2000-01-11 | 2001-07-17 | Allergan Sales, Inc. | Method for treating a pancreatic disorder with a neurotoxin |
| WO2001079837A1 (en) | 2000-04-12 | 2001-10-25 | Repligen Corporation | Methylxanthines in the diagnosis and treatment of autistic disorder |
| WO2003045322A2 (en) | 2001-11-28 | 2003-06-05 | Schering Corporation | Method for treating and preventing pancreatitis |
-
2004
- 2004-12-08 US US11/007,490 patent/US7381698B2/en not_active Expired - Lifetime
- 2004-12-10 WO PCT/US2004/041368 patent/WO2005058233A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005058233B1 (en) | Methods for treatment of acute pancreatitis | |
| Malandro et al. | Effect of low-protein diet-induced intrauterine growth retardation on rat placental amino acid transport | |
| Matthews et al. | Peptide absorption | |
| Vesely et al. | Atrial natriuretic prohormone peptides 1–30, 31–67, and 79–98 vasodilate the aorta | |
| Whitesst et al. | Hydrophobic surfactant-associated protein in whole lung surfactant and its importance for biophysical activity in lung surfactant extracts used for replacement therapy | |
| Wiedow et al. | Elafin is a potent inhibitor of proteinase 3 | |
| Hunter et al. | Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins | |
| Arbogast et al. | Which plasma factors bring about disturbance of endothelial function in pre-eclampsia? | |
| CA2275890A1 (en) | Stable liquid interferon formulations | |
| EP0566135A1 (en) | Transmucosal composition comprising a peptide and a cytidine derivative | |
| King et al. | Phylogenetic and anatomical distribution of somatostatin in vertebrates | |
| JP3176604B2 (en) | Factor Xa inhibitor and pharmaceutical composition containing the same | |
| IL135186A0 (en) | LIQUID INTERFERON-β FORMULATIONS | |
| US4342747A (en) | Colostrum-based composition for external use | |
| WO2002043661B1 (en) | Recombinant anti-cd30 antibodies and uses thereof | |
| GR3034925T3 (en) | Protein formulation comprising growth hormone. | |
| MY125414A (en) | Aminopropylphosphinic acids | |
| CA2188172A1 (en) | Human bone stimulating factor | |
| WO2002043746A3 (en) | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension | |
| WO1993005809A1 (en) | Pharmaceutical compositions comprising natriuretic peptides or neutral endopeptidase inhibitors for treating or preventing myointimal proliferation | |
| CA2196906A1 (en) | Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions | |
| JPS62103027A (en) | Ace inhibitor for ophthalmic spot degeneration | |
| JP2009511576A (en) | Leucine-rich composition | |
| RU99103692A (en) | AMINO ACID COMPOSITIONS AND THEIR APPLICATION IN IMMUNO DEPRESSION | |
| WO2002058589A3 (en) | Agents and methods for promoting bone growth |